糖原合成酶激酶3β参与神经病理性疼痛的研究进展

doi:10.13481/j.1671-587x.20200133

摘要/Abstract

摘要： 神经病理性疼痛（NP）是临床常见的疼痛类型，约占慢性疼痛患者的20%，因疼痛程度重、治疗难度大，严重危害患者的身心健康，其发病机制和治疗靶点一直是疼痛领域研究的热点。糖原合成酶激酶3（GSK-3）是丝氨酸/苏氨酸蛋白激酶的一种，最初被视为胰岛素依赖性糖原合成的关键蛋白激酶，随后越来越多的研究提示：GSK-3参与调节多种细胞功能活动，能够使多种底物发生磷酸化，包括细胞结构蛋白、转录因子和细胞分裂起始因子等，在蛋白质合成、信号传递、细胞增殖与分化、神经功能和肿瘤形成等多种细胞生理活动中扮演重要角色。GSK-3在哺乳动物中有GSK-3α和GSK-3β2种亚型，GSK-3β通过介导炎症反应参与NP的发生发展过程，应用其抑制剂可以减轻模型动物的NP症状。现对GSK-3β影响NP病理过程的相关文献进行综述，总结GSK-3β在NP中的作用，为NP发病机制和治疗药物研发提供新的靶点和方向。

关键词: 糖原合成酶激酶3, 神经病理性疼痛, 炎症反应, 促炎因子, 神经递质

中图分类号:

R338

李安然, 连丽丽, 姚刚. 糖原合成酶激酶3β参与神经病理性疼痛的研究进展[J]. 吉林大学学报(医学版), 2020, 46(01): 188-193.

参考文献

[1] WRIGHT M E,RIZZOLO D.An update on the pharmacologic management and treatment of neuropathic pain[J].JAAPA,2017,30(3):13-17.
[2] KIGUCHI N,KOBAYASHI D, SAIKA F,et al. Pharmacological regulation of neuopathic pain driven by inflammatory macrophages[J].Int J Mol Sci, 2017,18(11):2296.
[3] 王乙茹,王浩伟,袁红斌.神经病理性疼痛的研究进展[J].国际麻醉学与复苏杂志,2018,39(2):165-169.
[4] ZHANG L Y, LIU Z H, ZHU Q, et al. Resolvin D2 relieving radicular pain is associated with regulation of inflammatory mediators, Akt/GSK-3β signal pathway and GPR18[J]. Neurochem Res, 2018, 43(12):2384-2392.
[5] HE X J, FAN L Y, WU Z H, et al. Gene expression profiles reveal key pathways and genes associated with neuropathic pain in patients with spinal cord injury[J]. Mol Med Rep, 2017, 15(4):2120-2128.
[6] 宾晓芸,姜明国,翁汉荣. 糖原合酶激酶-3,一个参与多种信号通路的重要调节因子[J].中国生物化学与分子生物学报,2013,29(12):1120-1127.
[7] SHINDE M Y, SIDOLI S, KULE KJ,et al.Phosphoproteomics reveals that glycogen synthase kinase-3 phosphorylates multiple splicing factors and is associated with alternative splicing[J].J Biol Chem,2017,292(44):18240-18255.
[8] MEDINA M,AVILA J.New insights into the role of glycogen synthase kinase-3 in Alzheimer's disease[J].Expert Opin Ther Targets,2014,18(1):69-77.
[9] MAIXNER D W,WENG H R.The role of glycogen synthase kinase 3 beta in neuro-inflammation and pain[J].J Pharm Pharmacol, 2013,1(1):1-34.
[10] LOCHHEAD P A, KINSTRIE R,SIBBET G,et al. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation[J].Mol Cell, 2006,24(4):627-633.
[11] TAKAHASHI-YANAGA F.Activator or inhibitor GSK-3 as a new drug target[J].Biochem Pharmacol, 2013,86(2):191-199.
[12] CORTÉS-VIEYRA R,BRAVO-PATIÑO A,VALDEZ-ALARCÓN J J,et al.Role of glycogen synthase kinase-3 beta in the inflammatory response caused by bacterial pathogens[J].J Inflamm(Lond),2012, 9(1):23.
[13] YUAN Y,WANG J Y,YUAN F,et al.Glycogen synthase kinase-3β contributes to remifentanil-induced postoperative hyperalgesia via regulating N-methyl-D-aspartate receptor trafficking[J]. Anesth Analg,2013,116(2):473-481.
[14] FORDE J E,DALE T C.Glycogen synthase kinase 3:A key regulator of cellular fate[J].Cell Mol Life Sci,2007,64(15):1930-1944.
[15] MARTIN M, REHANI K, JOPE R S,et al. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3[J]. Nat Immunol,2005,6(8):777-784.
[16] AJMONE-CAT M A, D'URSO MC, DI BLASIO G,et al.Glycogen synthase kinase 3 is part of the molecular machinery regulating the adaptive response to LPS stimulation in microglial cells[J]. Brain Behav Immun, 2016,55:225-235.
[17] GÖTSCHEL F, KERN C, LANG S, et al. Inhibition of GSK3 differentially modulates NF-κB, CREB, AP-1 and β-catenin signaling in hepatocytes, but fails to promote TNF-α-induced apoptosis[J]. Exp Cell Res,2008,314(6):1351-1366.
[18] BEUREL E, JOPE R S.Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain[J].J Neuroinflammation, 2009,6:9.
[19] ANTONIV T T,IVASHKIV L B.Interleukin-10-induced gene expression and suppressive functionare selectively modulated by the PI3K-Akt-GSK3 pathway GSK3[J].Immunology,2011,132(4):567-577.
[20] BEUREL E, MICHALEK S M,JOPE R S.Innate and adaptive immune responses regulated by glycogen synthase kinase-3(GSK3)[J].Trends Immunol,2010,31(1):24-31.
[21] CHENG Y Y,PARDO M,ARMINi R S,et al.Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior[J].Brain Behav Immun,2016,53:207-222.
[22] BAI L,CHANG H M, CHENG J C,et al.Lithium chloride increases COX-2 expression and PGE2 production in a human granulosa-Lutein SVOG cell line via a GSK-3β/β-catenin signaling pathway[J].Endocrinology,2017, 158(9):2813-2825.
[23] JING H E,YEN J H,GANEA D. A novel signaling pathway mediates the inhibition of CCL3/4 expression by prostaglandin E2[J].J Biol Chem,2004, 279(53):55176-55186.
[24] YUSKAITIS C J,JOPE R S.Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity[J].Cell Signal, 2009,21(2):264-273.
[25] WENG H R, GAO M, MAIXNER D W.Glycogen synthase kinase 3 beta regulates glial glutamate transporter protein expression in the spinal dorsal horn in rats with neuropathic pain[J].Exp Neurol,2014,252:18-27.
[26] LI Y Z, TANG X H, WANG C Y,et al.Glycogen synthase kinase-3β inhibition prevents remifentanil-induced postoperative hyperalgesia via regulating the expression and function of AMPA receptors[J]. Anesth Analg,2014,119(4):978-987.
[27] XU W T, ZHU M, YUAN S T,et al.Spinal CXCL5 contributes to nerve injury-induced neuropathic pain via modulating GSK-3β phosphorylation and activity in rats[J].Neurosci Lett,2016,634:52-59.
[28] GAO M, YAN X, WENG H R.Inhibition of glycogen synthase kinase 3β activity with lithium prevents and attenuates paclitaxel-induced neuropathic pain[J].Neuroscience,2013,254:301-311.
[29] MAIXNER D W, YAN X S, GAO M,et al.Adenosine monophosphate-activated protein kinase regulates interleukin-1β expression and glial glutamate transporter function in rodents with neuropathic pain[J]. Anesthesiology, 2015,122(6):1401-1413.
[30] MARTINS D F, ROSA A O, GADOTTI V M, et al.The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta,in mice[J].J Pain,2011,12(3):315-322.
[31] MAZZARDO-MARTINS L,MARTINS D F,STRAMOSK J,et al. Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice:evidence for the mechanisms of action[J].Neuroscience,2012,226:411-420.
[32] COLLOCA L, LUDMAN T, BOUHASSIRA D, et al. Neuropathic pain[J]. Nat Rev Dis Primers,2017,3:17002.
[33] 严广斌.神经病理性疼痛[J].中华关节外科杂志,2017,11(4):446-446.
[34] GAO Y J, JI R R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain[J]. Pharmacol Ther,2010,126(1):56-68.
[35] WIESELER-FRANK J, MAIER S F, WATKINS L R. Immune-to-brain communication dynamically modulates pain:physiological and pathological consequences[J]. Brain Behav Immun,2005,19(2):104-111.
[36] KWON B K, FISHER C G, DVORAK M F, et al. Strategies to promote neural repair and regeneration after spinal cord injury[J]. Spine,2005,30(17 Suppl):S3-13.
[37] RAGHAVENDRA V, TANGA F, DELEO J A. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy[J]. J Pharmacol Exp Ther,2003,306(2):624-630.
[38] RAMOS K M, LEWIS M T, MORGAN K N, et al. Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone:therapeutic efficacy in a range of experimental nervous system disorders[J].Neuroscience, 2010,169(4):1888-1900.
[39] DOYLE T, CHEN Z M, MUSCOLI C, et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain[J]. J Neurosci, 2012,32(18):6149-6160.
[40] LI C R,DENG T R, SHANG Z,et al. Blocking TRPA1 and TNF-α signal improves bortezomib-induced neuropathic pain[J].Cell Physiol Biochem,2018,51(5):2098-2110.
[41] WANG Y,JIANG H F,NI J,et al.Pharmacological stimulation of sigma-1 receptor promotes activation of astrocyte via ERK1/2 and GSK3β signaling pathway[J].Naunyn Schmiedebergs Arch Pharmacol,2019,392(7):1-12.
[42] LI X H,MIAO H H,ZHUO M.NMDA receptor dependent long-term potentiation in chronic pain[J].Neurochem Res,2019,44(3):531-538.
[43] JIANG E S, YAN X S, WENG H R. Glial glutamate transporter and glutamine synthetase regulate GABAergic synaptic strength in the spinal dorsal horn[J].J Neurochem,2012,121(4):526-536.
[44] LIPINA T V, KAIDANOVICH-BEILIN O, PATEL S,et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3[J]. Synapse,2011,65(3):234-248.
[45] 陈蕾,王欣.帕金森病疼痛[J].中国实用内科杂志,2019,39(9):766-768.